Investigating the association between medication adherence and health-related quality of life in COPD:Methodological challenges when using a proxy measure of adherence by Boland, Melinde R. S. et al.
  
 University of Groningen
Investigating the association between medication adherence and health-related quality of life
in COPD
Boland, Melinde R. S.; van Boven, Job F. M.; Kruis, Annemarije L.; Chavannes, Niels H.; van





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Boland, M. R. S., van Boven, J. F. M., Kruis, A. L., Chavannes, N. H., van der Molen, T., Goossens, L. M.
A., & Rutten-van Molken, M. P. M. H. (2016). Investigating the association between medication adherence
and health-related quality of life in COPD: Methodological challenges when using a proxy measure of
adherence. Respiratory Medicine, 110, 34-45. https://doi.org/10.1016/j.rmed.2015.11.008
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
lable at ScienceDirect
Respiratory Medicine 110 (2016) 34e45Contents lists avaiRespiratory Medicine
journal homepage: www.elsevier .com/locate/rmedInvestigating the association between medication adherence and
health-related quality of life in COPD: Methodological challenges
when using a proxy measure of adherence
Melinde R.S. Boland a, *, Job F.M. van Boven b, Annemarije L. Kruis c, Niels H. Chavannes c,
Thys van der Molen d, Lucas M.A. Goossens a, Maureen P.M.H. Rutten-van M€olken a
a Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University, P.O. Box 1738, 3000 DR Rotterdam, The
Netherlands
b Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen,
The Netherlands
c Department of Public Health and Primary Care, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
d Department of General Practice, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlandsa r t i c l e i n f o
Article history:
Received 24 July 2015
Received in revised form
29 October 2015
Accepted 13 November 2015






Chronic obstructive pulmonary disease
Quality-of-life* Corresponding author. Institute for Medical Tech
University, P.O. box 1738, 3000 DR Rotterdam, The N
E-mail address: boland@bmg.eur.nl (M.R.S. Boland
http://dx.doi.org/10.1016/j.rmed.2015.11.008
0954-6111/© 2015 Published by Elsevier Ltd.a b s t r a c t
Background: The association between non-adherence to medication and health-related quality-of-life
(HRQoL) in Chronic Obstructive Pulmonary Disease (COPD) remains poorly understood. Different ways to
deal with methodological challenges to estimate this association have probably contributed to conﬂicting
results.
Aim: To investigate the association between medication adherence and HRQoL, thereby illustrating
methodological challenges that need to be addressed.
Methods: We used longitudinal patient-level data from a cluster-randomized controlled trial (i.e.
RECODE) including three-year data on type and dose of COPD maintenance medication prescribed and
HRQoL (Clinical COPD Questionnaire [CCQ], st. George Respiratory Questionnaire [SGRQ], EuroQol 5-
dimensions [EQ-5D]) of 511 patients. A linear mixed model was used to assess the association be-
tween adherence and HRQoL using a ﬁxed cut-off of 80% of the proportion of days covered (PDC) to
deﬁne adherence. Subsequently, we investigated the impact of differences in disease severity; lifestyle;
and reversed causality, representing the methodological challenges. Additionally, we investigated the
impact of changing the deﬁnition of adherence.
Results: In unadjusted analyses, and analyses adjusting for demographic characteristics only, SGRQ score
was worse in the adherent compared to the non-adherent group. This association disappeared when
correcting for disease severity and/or lifestyle. A better SGRQ score was predictive of decreased adher-
ence in the following year. However, accounting for the previous HRQoL did not result in positive as-
sociations between adherence and HRQoL. When deﬁning four categories of adherence, patients with a
PDC between 80 and 99% had a signiﬁcantly worse SGRQ score compared to patients with a PDC <60%,
even after correction for lifestyle. There was no signiﬁcant association between adherence and CCQ or
EQ-5D.
Conclusion: This study showed persistent methodological challenges in the investigation of the effect of
medication adherence on HRQoL in COPD. A positive association of adherence and HRQoL was not found,
even after adjusting for lifestyle, disease severity, and previous HRQoL.
© 2015 Published by Elsevier Ltd.nology Assessment, Erasmus
etherlands.
).1. Introduction
According to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines, the two major goals in the treatment of
Chronic Obstructive Pulmonary Disease (COPD) are the prevention
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life (HRQoL) [1]. Besides smoking cessation and other non-
pharmacologic treatment, medication plays an important role in
the current treatment of COPD. The efﬁcacy of currently available
maintenance medication for COPD has been shown in numerous
studies, mainly performed in well-controlled settings with highly
motivated patients and who demonstrate good medication adher-
ence [2,3]. However, medication adherence is considerable lower in
daily practice [4e6]. Hence, the positive results found in random-
ized controlled clinical trials may be less in real-life [4e6]. Two
recent reviews evaluated the consequences of non-adherence for
HRQoL in patients with COPD [7,8]. They found that at least 50% of
the studies reported no or negative associations between medica-
tion adherence and HRQoL and they concluded that the association
between non-adherence and HRQoL remains poorly understood.
Researchers are facing several methodological challenges such as
the possibility of confounding by disease severity, healthy lifestyle,
and reversed causality. Different ways to overcome these chal-
lenges have probably contributed to the conﬂicting results that
were reported with respect to the direction of the association
(positive or negative) [7,8]. A more systematic comparison of
different methods to deal with these challengesmight contribute to
a better understanding of the causal pathway of the association
between adherence and HRQoL and would allow tailored in-
terventions to optimize COPD treatment.
We used longitudinal patient-level data from the RECODE study,
the largest 2-year cluster randomized trial in 40 primary care
groups (N ¼ 1086) comparing a COPD disease management pro-
gram with usual care, to investigate the association between
medication adherence and HRQoL [9,10]. As part of this trial, data
on medication prescribed during the 2-year trial period as well as
the year prior to the trial were extracted from the general practi-
tioners' (GP) electronic medical records (EMR). During the same 2-
year period, patients' HRQoL was periodically assessed as part of
the trial. Hence, the RECODE-dataset provides a unique opportunity
to investigate the association between medication adherence and
HRQoL, while systematically investigating the role of disease
severity and healthy lifestyle in this association. The dataset also
allowed us to study reversed causality, i.e. whether adherence in a
particular year was inﬂuenced by HRQoL in the year before.
2. Methods
2.1. Study population
RECODE was a two-year cluster randomized trial including 20
primary care teams who were randomized to the intervention
group that implemented an integrated care program and 20 teams
whowere randomized to the usual care group. From these 40 teams
we recruited 1086 patients with physician-diagnosed COPD ac-
cording to the GOLD guidelines [1] between 2010 and 2011.
Exclusion criteria were terminal illnesses, dementia, cognitive
impairment, inability to complete questionnaires in Dutch, and
hard drug or alcohol abuse. Other co-morbidity was not an exclu-
sion criterion. The COPD patients in the RECODE trial were found to
be representative of the COPD population treated in primary care in
the Netherlands, i.e. the enrolled patients were mainly elderly, (ex)
smokers, had moderate COPD which was reﬂected by a mean post-
bronchodilator Forced expiratory volume in 1 (FEV1) of 68% pre-
dicted, and substantial co-morbidities [9]. All participants provided
written informed consent before participation and the RECODE
study was approved by the medical ethics committee of the Leiden
University Medical Centre (Netherlands Trial Register [NTR]
NTR2268).
For the current study, we included all RECODE patients from 23of the 40 RECODE primary care groups with at least two pre-
scriptions for COPD maintenance medication in one year and
complete HRQoL records in that same year. Patients from the
intervention group as well as the control group were included. The
remaining practices and patients were excluded because data on
type of medication and dosage prescribed could not be extracted
from the EMRs.2.2. Drug adherence
The COPD maintenance medication included long-acting b2-
agonists (LABA), long-acting muscarinic antagonists (LAMA),
inhaled corticosteroids (ICS), or ﬁxed-dose LABA/ICS combinations.
Medication prescriptions and prescribed daily doses were extracted
from the EMR of the GPs. For each year, adherencewas calculated as
the proportion of days covered (PDC), deﬁned as the proportion of
days in a year that a patient had COPD medication available. This is
calculated by the sum of all drug doses supplied divided by the
daily dosing regimen, divided by 365 days. This method is used in
various previous adherence studies in COPD [11e13]. For pre-
scriptions extending beyond the end of the analysis period, the
days covered were truncated at the end of the period. The average
PDC was used if patients used medications from different mainte-
nance medication categories (LABA, LAMA, ICS, LABA/ICS combi-
nations). Patients were classiﬁed as adherent if their (average) PDC
equalled or exceeded 80%. This threshold is frequently used in
adherence studies, also in COPD [12,14e17]. In sensitivity analyses,
we investigate the impact of changing the deﬁnition of adherence
by using (i) a categorical variable with four categories of PDC, i. e
<60%, 60e79%, 80e99%, >99%, (ii) PDC as a continuous variable,
and (iii) the minimum (or maximum) PDC if patients used medi-
cations from different maintenance medication categories (LABA,
LAMA, ICS, LABA/ICS combinations).2.3. Data collection
We used the following variables in our analysis:
- HRQoL, which was measured using the Clinical COPD Ques-
tionnaire (CCQ) [18,19], the Saint George's Respiratory Ques-
tionnaire (SGRQ) [20,21] and the 3-level EuroQoL-5Dimensions
(EQ-5D) [22] at baseline, after 1 year and after 2 years. The ﬁrst
two questionnaires (CCQ and SGRQ) are COPD-speciﬁc in-
struments and the EQ-5D is a generic HRQoL instrument used to
calculate utilities. Note that a higher score on SGRQ and CCQ
indicates a worse HRQoL, whereas a higher score on EQ-5D in-
dicates a better HRQoL. These questionnaires were measured at
baseline, 12 and 24 months.
- Socio-demographic factors (age, gender, level of education),
which were assessed at baseline.
- Forced expiratory volume in 1 s as percentage of the predicted
value (FEV1%pred), which was measured at baseline.
- History of exacerbations (moderate and severe). A moderate
exacerbation was deﬁned as a worsening of COPD symptoms
that led a patient's clinician to prescribe systemic corticoste-
roids and/or antibiotics, but did not require hospitalization. This
information was extracted from the EMR. A severe exacerbation
was deﬁned as a worsening of COPD symptoms that required a
hospital admission. Hospital admissions were obtained from the
resource use questionnaires completed by the patients and
conﬁrmed by the EMR. The resource use questionnaire was
measured at baseline, 6, 9, 12, 18 and 24 months.
- The Medical Research Council (MRC) dyspnoea scale [23]. This
was measured at baseline, 12 and 24 months.
M.R.S. Boland et al. / Respiratory Medicine 110 (2016) 34e4536- Charlson Comorbidity Index, which was measured at baseline
[24].
- Level of physical activity, which was calculated from the Inter-
national Physical Activity Questionnaire (IPAQ) by multiplying
the frequency (in days) and duration (in minutes) of walking,
moderateeintensity activities, and vigorouseintensity activities
in terms of the energy requirements, to yield a score in meta-
bolic equivalent time (MET) minutes [25]. This was measured at
baseline, 12 and 24 months.
- Self-efﬁcacy from the Self-Management Ability Scale-30 (SMAS-
30) [26]. This was measured at baseline, 12 and 24 months
- Smoking status (smoker or no smoker), which was measured at
baseline, 12 and 24 months.2.4. Statistical analysis
We investigated the association between adherence during one
year with HRQoL at the end of this year, i.e. the association between
adherence during the ﬁrst trial-year and HRQoL at 12 months, and
adherence over the second trial-year and HRQoL at 24 months. We
used linear mixed models to assess this association using a ﬁxed
cut-off of 80% to deﬁne adherent (80%) and non-adherent patients
(<80%). We investigated the interaction between trial-arm and
medication adherence to see if both groups in the trial could be
combined, i.e. if the impact of adherence to COPD medication on
HRQoL was different between the intervention group and the usual
care group. Because there was no signiﬁcant interaction, the data of
the two groups were combined. There was no interaction because
the RECODE intervention did not speciﬁcally target adherence and
adherence to COPDmedication and (change in) HRQoL in these two
groups were comparable (data not shown). The analyses were
performed using STATA (version 13) and statistical signiﬁcance of
results were considered at 5% level.
2.5. Base-case analyses
We started with a linear mixed model with a random intercept
and no confounders, thereafter, we included age, gender and level
of education (0 high education; 1 low education [deﬁned as no or
only primary education]), but no other confounders. Subsequently,
this simple, though often used analysis, was expanded. First, by
controlling for disease severity, second, by controlling for healthy
lifestyle and third, by investigating potential reversed causality.
These three analyses represent the challenges that researchers are
facing when adequately assessing the association between medi-
cation adherence and HRQoL [8]. A more detailed description of
these challenges is given below.
2.5.1. Challenge 1: adequately correcting for disease severity
It is likely that more severely ill patients have a higher need for
medication and as a result they may be more adherent [27,28].
Hence, a correction for differences in disease severity between
adherent and non-adherent patients is necessary. Therefore, we
estimated a linear mixed model with a random intercept and
correction for four indicators of disease severity, i.e. the FEV1%pred
at baseline, the total exacerbation rate (moderate or severe) in the
12months prior to the adherencemeasurement, theMRC dyspnoea
scale [23] at the start of the adherence measurement and the
Charlson comorbidity index at baseline [24].
2.5.2. Challenge 2: addressing a potential healthy-adherer effect
Some studies suggested that therapy adherence is an indicator
of overall healthy lifestyle. It is argued that those who take good
care of their health in general, by adopting a healthy lifestyle, aremore likely to be adherent to medication. Hence, a positive asso-
ciation between adherence and HRQoL could be caused by a
healthy lifestyle in general. This is referred to as the “healthy-
adherer effect” [12,29]. Therefore, we estimated a linear mixed
model with a random intercept and including three variables that
are indicators of a healthy lifestyle in general measured at the same
time as the HRQoL. These variables were smoking status (smoker or
no smoker), level of physical activity and self-efﬁcacy. We hy-
pothesized that a higher score on IPAQ or self-efﬁcacy and non-
smoking status would indicate a healthier lifestyle. In this way,
we aimed to ‘correct’ for a possible healthy-adherer effect.2.5.3. Challenge 3: investigating potential reversed causality
In the previous analyses, we assessed the effect of adherence
during a particular year on HRQoL at the end of that same year.
However, reversed causality may be present, meaning that HRQoL
measured at the beginning of a year may inﬂuence adherence to
medication during that year. A better HRQoL may improve adher-
ence (“I am feeling good so I need to keep taking my medication”),
but it may also lead to a reduction in adherence (“because I am
feeling good I need less medication”) [30]. To unravel this associ-
ation, we studied whether an improvement greater than or equal to
the minimal clinically important difference (MCID) in HRQoL (4
points on the SGRQ [21];.4 points on the CCQ [19]) during the ﬁrst
trial-year changed the PDC in the second trial-year using a t-test. In
addition, we account for the previous HRQoL in a linear model with
an unstructured covariance matrix for repeated measures.3. Results
3.1. Dataset characteristics
The 23 primary care groups that had complete EMR regarding
type and dosage of medication prescribed, enrolled 658 patients
into the RECODE trial (61% of all patients in the trial). From these
658 patients, we excluded 147 patients (22%) because they did not
have at least two prescriptions for COPD maintenance medication
in one year and complete HRQoL records in that same year. In total,
511 COPD patients have been included in this study. The patient
characteristics were very similar to those in the total RECODE study
population (Appendix 1). For each year, we calculated the PDC for
the 511 participants. The majority of the COPD patients (>74%) are
using LABA/ICS combinations and the average PDC of COPD main-
tenance medication is 81%, 76%, 78% in respectively year 0, year 1
and year 2 (Appendix 2).
Table 1 presents the patient characteristics of the dataset split
into adherent and non-adherent patients. The proportions of pa-
tients who were adherent were 63%, 57% and 58% in year 0, 1 and 2,
respectively. The proportion of low educated patients was signiﬁ-
cantly higher in the non-adherent group (49%) compared to the
adherent group (38%) in year 0. Furthermore, the adherent group
had worse average MRC and SGRQ scores compared to the non-
adherent group in year two.3.2. Base-case analyses
The results of the base-case analyses are shown in Table 2. In the
unadjusted analyses the adherent group had worse quality of life
than the non-adherent group. In the case of the SGRQ, this differ-
ence was statististically signiﬁcant (P ¼ 0.034) and close to clinical-
relevance threshold of 4 [21]. This difference diminished after
adjusting for the sociodemographic variables age, sex, and educa-
tion (P ¼ 0.098).
Table 1
Patients' characteristics of adherent and non-adherent COPD patients.













Age (years) (SD) 67 (11) 68 (11) 68 (11) 68 (10) 67 (11) 68 (10)
Male (%) 45.0 45.9 50.2 50.4 54.8 49.6
Low education (%) 48.7 37.5a 39.0 42.7 39.8 42.7
FEV1%pred (SD) 67.8 (20.0) 65.1 (20.1) 67.0 (18.1) 65.2 (21.0) 67.7 (17.8) 64.4 (20.3)
Exacerbations (SD) .42 (.87) .50 (.99) .50 (1.04) .68 (1.19) 1.04 (1.95) 1.42 (2.18)
MRC dyspnoea (SD) 2.1 (1.3) 2.0 (1.3) 2.1 (1.3) 2.3 (1.3) 2.2 (1.3) 2.5 (1.4)a
Charlson comorbidity
index (SD)
2.4 (1.2) 2.3 (1.2) 2.3 (1.3) 2.3 (1.1) 2.3 (1.3) 2.3 (1.2)
Total MET minutes (SD) 3114 (4940) 2539 (4921) 3168 (4807) 2716 (4471) 3325 (4462) 2682 (4253)
Self-efﬁcacy (SD) 64.8 (17.7) 65.5 (17.2) 64.2 (16.9) 62.9 (16.8) 66.0 (18.5) 64.2 (16.3)
Smoker (%) 39.6 33.4 30.9 30.2 49.0 43.8
CCQ (SD) 1.54(1.03) 1.41 (.89) 1.49 (.96) 1.53 (.96) 1.72 (.95) 1.88 (1.02)
SGRQ (SD) 35.7 (21.0) 34.6 (19.9) 34.5 (20.9) 35.6 (20.2) 33.7 (21.5) 39.7 (23.5)a
EQ-5D utility (SD) .74 (.26) .74 (.27) .72 (.26) .72 (.27) .78 (.25) .80 (.21)
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
a Signiﬁcant (P < 0.05); SD¼ Standard Deviation; PDC¼ Proportion of Days Covered; FEV1%pred¼ predicted percentage of Forced Expiratory Volume in 1 s; MRC¼Medical
Research Council; MET ¼Metabolic Equivalent Time; CCQ¼ Clinical COPD Questionnaire; SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions.
Table 2
Linear mixed models with and without correcting for demographics, disease severity and healthy-lifestyle variables.
b P-value b P-value b P-value b P-value b P-value
Dependent variable CCQ
Intercept 1.46 <.01 1.30 <.01 1.18 <.01 2.72 <.01 1.88 <.01
Adherent (PDC  80%) .09 .17 .07 .31 .01 .84 .12 .14 .07 .28
Demographics Year 2 .30 <.01 .30 <.01 .21 <.01 .32 <.01 .21 <.01
Age .0001 .97 .01 .02 .005 .26 .01 .06
Men .03 .72 .08 .15 .04 .61 .08 .24
Low education .45 <.01 .22 <.01 .36 <.01 .16 .02
Disease severity FEV1% pred .005 <.01 .005 .01
Exacerbations .15 <.01 .14 <.01
MRC dyspnoea .38 <.01 .37 <.01
Charlson comorbidity index .06 .01 .01 .69
Healthy lifestyle Physical activity (MET minutes) 2.1e-5 .04 7.5e-6 .38
Self-efﬁcacy .02 <.01 .01 <.01
Smoker .14 .096 .14 .06
Observations used in the analysis (N) 825 754 726 542 524
Dependent variable SGRQ
Intercept 33.3 <.01 24.6 <.01 21.9 <.01 58.9 <.01 40.4 <.01
Adherent (PDC  80%) 3.27 .03 2.58 .098 .51 .67 2.29 .18 1.01 .44
Demographics Year 2 2.02 .19 2.35 .13 .55 .64 2.94 .11 .36 .80
Age .09 .25 .08 .21 .03 .73 .06 .38
Men 1.90 .23 1.00 .41 3.39 .05 .32 .82
Low education 10.1 <.01 4.62 <.01 9.28 <.01 4.47 <.01
Disease severity FEV1% pred .11 <.01 .15 <.01
Exacerbations 3.47 <.01 3.71 <.01
MRC dyspnoea 9.14 <.01 8.36 <.01
Charlson comorbidity index 1.37 <.01 .77 .18
Healthy lifestyle Physical activity (MET minutes) .001 .02 1.9e-4 .25
Self-efﬁcacy .37 <.01 .22 <.01
Smoker .52 .78 .52 .72
Observations used in the analysis (N) 794 729 704 542 523
Dependent variable EQ-5D
Intercept .72 <.01 .65 <.01 .80 <.01 .35 <.01 .63 <.01
Adherent (PDC  80%) .01 .77 .01 .62 .02 .27 .004 .85 .01 .63
Demographics Year 2 .07 <.01 .06 <.01 .07 <.01 .06 <.01 .07 <.01
Age .001 .22 .002 .01 .001 .29 .001 .18
Men .06 <.01 .04 .03 .07 <.01 .04 .02
Low education .09 <.01 .05 <.01 .08 <.01 .05 .02
Disease severity FEV1% pred .0002 .62 .001 .32
Exacerbations .02 <.01 .02 .02
MRC dyspnoea .05 <.01 .04 <.01
Charlson comorbidity index .04 <.01 .03 <.01
Healthy lifestyle Physical activity (MET minutes) 7.0e-7 .77 4.6e-6 .05
Self-efﬁcacy .005 <.01 .004 <.01
Smoker .02 .37 .03 .17
Observations used in the analysis (N) 827 760 733 555 535
CCQ¼ Clinical COPD Questionnaire; SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions; FEV1% pred ¼ predicted percentage of Forced
Expiratory Volume in 1 s; MRC¼Medical Research Council; IPAQ¼ International Physical Activity Questionnaire; MET¼Metabolic Equivalent Time, PDC¼ Proportion of Days
Covered.
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
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Table 3
Clinically important difference in HRQoL in the ﬁrst trial-year and changed adherence in the second trial-year.
MCID at year 1 DPDC (PDC year 2-PDC year 1) Mean difference P-value Observations (N)
Improvement CCQ No .1% 2.4% .326 437
Yes 2.5%
SGRQ No 2.0% 4.6% .038 422
Yes 2.6%
Deterioration CCQ No 1.3% 2.0% .373 437
Yes .7%
SGRQ No .8% 1.5% .502 422
Yes .7%
HRQoL ¼ health-related quality of life; MCID ¼Minimal Clinically Important Difference; CCQ: Clinical COPD Questionnaire; SGRQ: Saint George's Respiratory Questionnaire;
PDC¼ Proportion of Days Covered, Unpaired t test, no MCID vs MCID.
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When indicators of disease severity (FEV1%pred, prior exacer-
bations, MRC dyspnoea score, Charlson comorbidity index) were
added, the associations between adherence and HRQoL decreased,
regardless of how we measured HRQoL (Table 2).
3.4. Correcting for healthy lifestyle
When further adding indicators of a healthy lifestyle in general
(level of physical activity, self-efﬁcacy and smoking status), we did
not ﬁnd a relationship between adherence and HRQoL either
(Table 2).
3.5. Reversed causality
The PDC of patients with an improvement greater than or equal
to the MCID in SGRQ score (i.e. 4 points) over the ﬁrst trial-year
decreased on average with 2.6% during the second trial-year year,
whereas the PDC of patients without such an improvement
increased with 2%, leading to a signiﬁcant difference in change in
PDC of 4.6% between these two groups (Table 3). This indicates that
improved HRQoL may reduce future adherence. This association
was found for the SGRQ but not for the CCQ, nor did we ﬁnd an
association between a clinically relevant deterioration in HRQoL
and an improved adherence in the next year (Table 3). However,
accounting for the previous HRQoL (using a linear model with
unstructured covariance matrix for repeated measures), still did
not result in the expected positive associations between adherence
and HRQoL, regardless of how we measured HRQoL (Appendix 3).
3.6. Sensitivity analyses
The results of the sensitivity analyses to investigate the impact
of changing the deﬁnition of adherence are presented in Appendix
4 to 7. Appendix 4 shows the results of the sensitivity analyses in
which we used four categories of PDC (i.e. <60%, 60e79%, 80e99%,
>99%). Patients with a PDC of 80e99% had a signiﬁcantly higher
SGRQ score than patients with a PDC <60%, indicating a worse
HRQoL. This difference of 4.47 exceeds the MCID of 4 points on the
SGRQ [21]. Also after correction for demographics and healthy
lifestyle variables, patients with a PDC of 80e99% had a signiﬁ-
cantly higher SGRQ score than patients with a PDC <60%. After
controlling for disease severity, patients with a PDC of 80e99% had
no longer a signiﬁcantly higher SGRQ score. Using PDC as a
continuous variable, we did not ﬁnd an association between
adherence and HRQoL, independent of whether we corrected for
demographics, healthy lifestyle and disease severity (Appendix 5).
Neither did we ﬁnd an association with adherence using the min-
imum PDC if patients used medication from different maintenance
medication categories (Appendix 6). However, when using themaximum PDC if patients used medication from different mainte-
nance medication categories, adherent patients had a signiﬁcantly
higher SGRQ and CCQ score than non-adherent patients, even after
correcting for demographics (Appendix 7). These differences in the
SGRQ score (5.75 and 4.81) exceed the MCID of 4 points but the
differences in the CCQ score (.17 and .15) did not exceed theMCID of
.4 points.
4. Discussion
This study investigated the association between medication
adherence and HRQoL, thereby illustrating methodological chal-
lenges that need to be addressed. These challenges were the pos-
sibility of confounding by (i) disease severity, (ii) healthy lifestyle,
(iii) and reversed causality. In unadjusted analyses, we found that
adherent patients had a worse SGRQ score. This association dis-
appeared when we corrected for healthy lifestyle and, especially,
disease severity. This demonstrates the importance of this correc-
tion. However, after this correction we did not ﬁnd that better
adherence led to better HRQoL. We found some indications of
reversed causality because an improvement in SGRQ score during
the ﬁrst year was associated with a reduction in adherence during
the second year, whereas no improvement in SGRQ was associated
with an increase in adherence.
The ﬁrst challenge sought to determine the impact of correcting
for disease severity. Our hypothesis was that more severely ill pa-
tients have a higher need for medication and as a result they are
more likely to be adherent, thus making a correction for disease
severity necessary when studying the association between adher-
ence and HRQoL. Turner and colleagues [31] and Ingebrigtsen and
colleagues [27] found that FEV1%pred was worse in the adherent
group compared to the non-adherent group, while the FEV1%pred
did not signiﬁcantly differ between these groups in two other
studies [32,33]. Previous studies also found that adherence in COPD
was inﬂuenced by other indicators of disease severity; shortness of
breath [27,31], exacerbations [27], and comorbidities such as
depression [28,34]. We only found in the second year, that the
adherent patients did have a worse MRC dyspnoea and SGRQ score
than the non-adherent patients. Nevertheless, correction for dis-
ease severity with the variables FEV1%pred, exacerbations, MRC
dyspnoea scale and Charlson comorbidity index removed the as-
sociation between better adherence and worse SGRQ score in this
study. Therefore, it is of important to accurately account for these
indicators of COPD disease severity. Only one previous study [35]
that investigated the inﬂuence of adherence in COPD medication
on HRQol included an indicator of disease severity (depression) in
their analyses. With correction for depression score, they found
that better adherence was associated with improved HRQoL (SGRQ
score). Unfortunately, they did not report results without this
correction.
In the second challenge, we determined the impact of a
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who take good care of their health in general (healthy lifestyle) are
more likely to be adherent to medication, thus making it important
to correct for differences in lifestyle. We did not ﬁnd any statisti-
cally signiﬁcant differences in smoking status, physical activity and
self-efﬁcacy between the adherent and non-adherent group. This
was in accordancewith, Turner and colleagues [31], who also found
that the exercise level between the adherent and non-adherent
group did not differ. In contrast, other studies did seem to be
consistent with the “healthy-adherer” impact: the proportion of
smokers [28,31,33] and drinkers [31] was lower among the adherer
group and COPD patients with higher self-efﬁcacy scores [28] were
more likely to be classiﬁed as adherent.
The impact of correcting for indicators of a healthy lifestyle in
our study depended on the deﬁnition of adherence. When we
deﬁned adherence as a PDC 80%, correction for lifestyle reduced
the association between a better adherence and a worse SGRQ
score and left it statistically non-signiﬁcant. Still, the reduction of
the association was markedly smaller than when we adjusted for
disease severity. When we used categories for PDC-levels, patients
with good adherence (PDC 80%e99%) still had a relatively bad
average SGRQ score. We found similar results if we used the
maximum PDC, i.e. good adherence was associated with worse CCQ
and SGRQ scores even after correcting for healthy lifestyle
variables.
In the third challenge, we investigated the presence of potential
reversed causality. In line with Agh and colleagues [8], a better
SGRQ score was predictive of decreased adherence to COPD med-
ications during that year. However, accounting for previous HRQoL
did not result in positive associations between adherence and
HRQoL, regardless of how we measured HRQoL. It is plausible that
more frequent measurements of HRQoL and clinical variables,
combined with adherence calculations over shorter intervals,
would lead to better estimates of the causal effect of adherence on
HRQoL. Hence, it is likely that HRQoL at the end of each year was
mainly affected by adherence in the weeks or months immediately
prior to the measurement, and not as much by adherence over the
full year. Similarly, adherence could have been inﬂuenced by cur-
rent disease symptoms, more than by HRQoL in a more distant past.
We did not ﬁnd a linear relationship between the degree of
medication adherence and HRQoL. Patients with a PDC of 80e99%
had a substantially and signiﬁcantly worse SGRQ score than pa-
tients with a PDC below 60%, but patients with a PDC of 100% did
not. None of the previous adherence studies in COPD performed
analyses using various cut-off values to deﬁne adherence and only
two studies [32,33] explained the reason for their cut-off value
chosen. We advise further studies to perform sensitivity analysis
with different subgroups of adherent levels, including a group with
optimal- and over-users.
It was interesting that we have not found any association be-
tween adherence and the generic HRQoL instrument EQ-5D
whereas we did ﬁnd an association between adherence and the
disease-speciﬁc HRQoL instruments (SGRQ and CCQ). These ﬁnd-
ings might be due to the fact that disease-speciﬁc questionnaires
seem to be more sensitive in ﬁnding differences in symptoms that
are not usually picked up by the generic instruments [36e38]. We
therefore advise researchers to use disease-speciﬁc instruments
when assessing the relationship between adherence and HRQoL.
Most previous studies on the association between adherence
and health outcomes relied on proxies for disease severity because
other indicators of disease severity (e.g. lung function) were lacking
[13,39]. Using the RECODE study, we were able to use various in-
dicators of disease severity. Moreover, we were able to investigate
the association between adherence and both generic and disease-
speciﬁc HRQoL. Furthermore, due to (i) the inclusion of RECODEpatients from the intervention group as well as the control group
and (ii) the repeated measurements of the patients, we included
over 800 observations in our analyses.
This study has some limitations. One is that the adherence data
of the present study were based on EMR. These data do not indicate
whether a patient has actually ﬁlled the prescription and has
subsequently taken the medication (appropriately). Hence, it is
likely that adherence has been overestimated. Probably the only
way to do it right is by using real-time medication monitoring in-
halers, i.e. inhalers that send a signal to a data centre each time the
button is pressed. Even then, you cannot be 100% sure that the
medication is actually inhaled. However since this type of moni-
toring is still very costly and difﬁcult to implement in real life we
have to rely on proxy measures of adherence. Prescription data and
pharmacy dispensing data are often used as proxies, and in our
study we have used prescription data because it is generally more
accurate than estimations from physicians and self-reports by pa-
tients [16]. In the Netherlands, a patient has to actively request a
repeated prescription of maintenance medication, because physi-
cians are not allowed to prescribe medication for more than 3
months of use. Furthermore, patients have to pay for these pre-
scriptions, out-of-pocket, as long as the maximum amount of pa-
tient co-payment (currently V375 per year) has not been paid. This
maximum amount of co-payment is obligatory. Hence, we can
safely assume that there is a positive association between pre-
scribing, dispensing and use of medication. Second, we did not
evaluate the effect of medication overuse. This is an important issue
for future research as we did not ﬁnd a continuously positive
relationship between the degree of medication adherence and
HRQoL, i.e. those with medication overuse (PDC>99%) did not have
a better HRQoL than those with a PCD<60%. Third, patients regis-
tered in primary care groups that had incomplete EMRwith respect
to medication could not be included in this study. However, this is
due to the fact that we were not able to extract data on type of
medication and dosage prescribed from all of the different EMR
systems of the GPs and not an indication of a systematic difference
between practices. Indeed, the baseline characteristics of the subset
of RECODE patients in the current study were comparable to
characteristics of the full RECODE dataset.
To conclude, we were unable to ﬁnd a positive association be-
tween COPD medication adherence and HRQoL. Even after adjust-
ing for potential confounders such as demographics, disease
severity and healthy lifestyle variables, we did not ﬁnd a positive
relationship. Our analyses demonstrated that the lack of correction
for disease severity and healthy lifestyle variables may even result
in a reversed association; patients with good COPD medication
adherence had a worse HRQoL compared to patients with poor
COPD medication adherence. Further studies should improve the
adjustment for disease severity and previous HRQoL, perhaps by
using shorter intervals.Acknowledgements
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Baseline characteristics of this study compared to the total RECODE population.
Characteristic Subset of RECODE population (N ¼ 511) Total RECODE population (N ¼ 1.086) P-value
Age (years) (SD) 68.0 (10.7) 68.3 (11.2) .621
Male (%) 51.0 53.9 .235
Low education (%) 41.5 40.3 .684
FEV1%pred 66.1 67.8 .123
Charlson comorbidity index (SD) 2.3 (1.2) 2.3 (1.3) .421
Physical activity (MET minutes) (SD) 2.641 (4.241) 2.925 (4.683) .247
Self-efﬁcacy (SD) 65.2 (17.6) 65.3 (17.4) .921
Current smoker (%) 37.3 36.7 .817
CCQ (SD) 1.47 (.94) 1.50 (.97) .543
SGRQ (SD) 35.0 (20.3) 35.6 (20.5) .568
EQ-5D utility (SD) .74 (.27) .74 (.26) .852
SD¼ Standard Deviation; FEV1% pred ¼ predicted percentage of Forced Expiratory Volume in 1 s; MET ¼ Metabolic Equivalent Time; CCQ¼ Clinical COPD Questionnaire;
SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions.
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
Appendix 2
Proportion of days covered medication according to type of medication.
Year N (%) Proportion of days covered Standard deviation
Year 0 Inhaled corticosteroids 73 (16) 79.3% 26.6%
Long-acting muscarinic antagonists 56 (12) 76.3% 27.4%
LABA/ICS combinations 312 (67) 79.1% 25.9%
b2-agonists 285 (61) 86.1% 22.5%
Overall 465 (100) 80.9% 23.5%
Year 1 Inhaled corticosteroids 79 (16) 77.9% 26.7%
Long-acting muscarinic antagonists 75 (15) 78.2% 27.4%
LABA/ICS combinations 354 (72) 74.7% 28.2%
b2-agonists 310 (63) 81.6% 25.0%
Overall 491 (100) 76.3% 25.4%
Year 2 Inhaled corticosteroids 75 (16) 77.9% 27.9%
Long-acting muscarinic antagonists 76 (16) 79.4% 25.3%
LABA/ICS combinations 331 (71) 76.2% 26.6%
b2-agonists 298 (64) 82.4% 22.7%
Overall 469 (100) 77.8% 24.0%
Appendix 3
Linear mixed models accounting for HRQoL in the previous year.
b P-value b P-value b P-value b P-value b P-value
Dependent variable CCQ
Intercept 1.50 <.01 1.34 <.01 1.18 <.01 2.69 <.01 2.11 <.01
Adherent (PDC  80%) .02 .77 ¡.003 .96 .01 .92 .03 .64 .07 .29
Demographics Year 2 .34 <.01 .34 <.01 .26 <.01 .35 <.01 .25 <.01
Age .0001 .98 .004 .19 .005 .32 .01 .09
Men .04 .62 .05 .50 .04 .71 .07 .33
Low education .48 <.01 .29 <.01 .36 <.01 .21 <.01
Disease severity FEV1% pred .01 <.01 .005 <.01
Exacerbations .09 <.01 .11 <.01
MRC dyspnoea .29 <.01 .31 <.01
Charlson comorbidity index .08 <.01 .03 .36
Healthy lifestyle Physical activity (MET minutes) 2.0e-5 .02 2.7e-6 .75
Self-efﬁcacy .02 <.01 .01 <.01
Smoker .18 .04 .14 .06
Observations used in the analysis (N) 825 754 726 542 524
Dependent variable SGRQ
Intercept 35.3 <.01 28.0 <.01 30.4 <.01 49.9 <.01 42.9 <.01
Adherent (PDC  80%) ¡.27 .82 ¡.27 .82 .30 .80 .85 .58 1.26 .36
Demographics Year 2 3.75 <.01 3.67 <.01 2.22 <.01 2.97 <.01 .89 .46
Age .07 .17 .02 .83 .01 .88 .05 .51
Men 2.72 <.01 .73 .64 3.07 .11 .53 .72
Low education 10.1 <.01 6.61 <.01 9.18 <.01 5.28 <.01
Disease severity FEV1% pred .21 <.01 .17 <.01
Exacerbations 1.73 <.01 2.93 <.01
MRC dyspnoea 5.28 <.01 7.13 <.01
Charlson comorbidity index 2.33 <.01 1.09 .08
Healthy lifestyle Physical activity (MET minutes) .0002 .18 1.8e4 .28
Self-efﬁcacy .29 <.01 .23 <.01
Smoker 1.19 .53 .09 .96
Observations used in the analysis (N) 794 729 704 542 523
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Appendix 3 (continued )
b P-value b P-value b P-value b P-value b P-value
Dependent variable EQ-5D
Intercept .72 <.01 .68 <.01 .77 <.01 .33 <.01 .56 <.01
Adherent (PDC  80%) .002 .89 .004 .80 .01 .53 .006 .78 .01 .71
Demographics Year 2 .07 <.01 .06 <.01 .07 <.01 .05 <.01 .06 <.01
Age .001 .47 .002 .10 .001 .21 .002 .13
Men .06 <.01 .04 .05 .07 <.01 .05 .02
Low education .09 <.01 .06 <.01 .08 <.01 .05 .02
Disease severity FEV1% pred .0002 .67 .0003 .59
Exacerbations .02 .03 .02 .03
MRC dyspnoea .03 <.01 .03 <.01
Charlson comorbidity index .04 <.01 .03 <.01
Healthy lifestyle Physical activity (MET minutes) 2.9e-7 .90 3.3e-6 .16
Self-efﬁcacy .005 <.01 .004 <.01
Smoker .01 .54 .02 .32
Observations used in the analysis (N) 827 760 733 555 535
CCQ¼ Clinical COPD Questionnaire; SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions; FEV1% pred ¼ predicted percentage of Forced
Expiratory Volume in 1 s; MRC¼Medical Research Council; IPAQ¼ International Physical Activity Questionnaire; MET¼Metabolic Equivalent Time, PDC¼ Proportion of Days
Covered.
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
Appendix 4
Linear mixed models using four categories of PDC.
b P-value b P-value b P-value b P-value b P-value
Dependent variable CCQ
Intercept 1.46 <.01 1.38 <.01 1.17 <.01 2.72 <.01 1.85 <.01
Adherence (PDC <60%) ref. ref. ref. ref. ref.
Adherence (PDC 60¡79%) ¡.01 .93 ¡.03 .75 .01 .95 .01 .90 .06 .53
Adherence (PDC 80e99%) .11 .21 .09 .33 .05 .49 .19 .07 .14 .09
Adherence (PDC >99%) .06 .58 .004 .97 ¡.05 .57 .02 .85 .03 .78
Demographics Time .30 <.01 1.32 <.01 .22 <.01 .33 <.01 .21 <.01
Age .0001 .99 .01 .02 .005 .25 .01 .05
Men .03 .72 .08 .15 .04 .60 .08 .23
Low education .45 <.01 .22 <.01 .35 <.01 .16 .03
Disease severity FEV1% pred .005 <.01 .004 .02
Exacerbations .15 <.01 .14 <.01
MRC dyspnoea .38 <.01 .37 <.01
Charlson comorbidity index .06 .01 .01 .64
Healthy lifestyle Physical activity (MET minutes) 2.1e-5 .04 8.0e-6 .35
Self-efﬁcacy .02 <.01 .01 <.01
Smoker .14 .09 .13 .06
Observations used in the analysis (N) 825 754 542 542 524
Dependent variable SGRQ
Intercept 32.9 <.01 25.0 <.01 21.7 <.01 59.1 <.01 40.2 <.01
Adherence (PDC <60%) ref. ref. ref. ref. ref.
Adherence (PDC 60e79%) .74 .75 ¡.24 .92 .07 .97 ¡.60 .81 .08 .97
Adherence (PDC 80e99%) 5.15 .01 4.30 .03 2.24 .15 4.21 .05 2.79 .10
Adherence (PDC >99%) .93 .68 ¡.55 .81 ¡2.22 .20 ¡1.46 .55 ¡1.78 .35
Demographics Year 2 2.06 .18 2.39 .12 .63 .59 3.20 .08 .67 <.01
Age .09 .27 .08 .18 .03 .72 .06 .35
Men 1.93 .22 .99 .41 3.46 .04 .34 .80
Low education 10.0 <.01 4.51 <.01 9.05 <.01 4.29 <.01
Disease severity FEV1% pred .11 <.01 .15 <.01
Exacerbations 3.46 <.01 3.67 <.01
MRC dyspnoea 9.14 <.01 8.34 <.01
Charlson comorbidity index 1.45 <.01 .89 .12
Healthy lifestyle Physical activity (MET minutes) .0004 .02 .0002 .23
Self-efﬁcacy .37 <.01 .23 <.01
Smoker .40 .83 .42 .77
Observations used in the analysis (N) 794 729 704 542 925
Dependent variable EQ-5D
Intercept .72 <.01 .65 <.01 .79 <.01 .36 <.01 .64 <.01
Adherence (PDC <60%) ref. ref. ref. ref. ref.
Adherence (PDC 60e79%) ¡.004 .87 .01 .78 .02 .48 ¡.04 .23 ¡.03 .32
Adherence (PDC 80e99%) .008 .73 .01 .63 .02 .31 ¡.02 .45 ¡.01 .57
Adherence (PDC >99%) ¡.004 .86 .01 .60 .03 .18 .001 .98 .01 .61
Demographics Year 2 .07 <.01 .06 <.01 .07 <.01 .06 <.01 .07 <.01
Age .001 .22 .002 .01 .001 .29 .001 .16
Men .06 <.01 .04 .03 .07 <.01 .04 .02
Low education .09 <.01 .05 <.01 .08 <.01 .04 .02
(continued on next page)
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Appendix 4 (continued )
b P-value b P-value b P-value b P-value b P-value
Disease severity FEV1% pred .0002 .62 .001 .27
Exacerbations .02 <.01 .02 .02
MRC dyspnoea .05 <.01 .04 <.01
Charlson comorbidity index .04 <.01 .03 <.01
Healthy lifestyle Physical activity (MET minutes) 8.5e-7 .72 4.7e-6 .04
Self-efﬁcacy .005 <.01 .004 <.01
Smoker .02 .37 .03 .17
Observations used in the analysis (N) 827 760 733 555 535
CCQ¼ Clinical COPD Questionnaire; SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions; PDC¼ Proportion of Days Covered; ref ¼ reference
group; FEV1% pred ¼ predicted percentage of Forced Expiratory Volume in 1 s; MRC ¼ Medical Research Council; IPAQ¼ International Physical Activity Questionnaire;
MET ¼ Metabolic Equivalent Time.
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
Appendix 5
Linear mixed models using PDC as a continuous variable.
b P-value b P-value b P-value b P-value b P-value
Dependent variable CCQ
Intercept 1.40 <.01 1.28 <.01 1.20 <.01 2.68 <.01 1.84 <.01
Adherence
(PDC continuous) .14 .29 .07 .62 ¡.03 .80 .17 .30 .12 .34
Demographics Year 2 .29 <.01 .30 <.01 .21 <.01 .32 <.01 .20 <.01
Age .0003 .94 .01 .03 .005 .24 .01 .06
Men .03 .69 .08 .16 .04 .59 .08 .24
Low education .45 <.01 .22 <.01 .36 <.01 .16 .02
Disease severity FEV1% pred .005 <.01 .004 .02
Exacerbations .15 <.01 .14 <.01
MRC dyspnoea .38 <.01 .37 <.01
Charlson comorbidity index .06 .01 .01 .73
Healthy lifestyle Physical activity (MET minutes) 2.1e-5 .04 7.5e-6 .37
Self-efﬁcacy .02 <.01 .01 <.01
Smoker .14 .11 .13 .07
Observations used in the analysis (N) 825 754 726 542 524
Dependent variable SGRQ
Intercept 31.4 <.01 23.7 <.01 22.5 <.01 59.0 <.01 40.8 <.01
Adherence (PDC continuous) 4.96 .11 2.86 .37 ¡.58 .81 1.86 .58 .34 .90
Demographics Year 2 1.94 .21 2.34 .13 .57 .63 2.93 .11 .35 .81
Age .09 .24 .07 .22 .03 .71 .06 .38
Men 1.98 .21 .97 .42 3.48 .04 .37 .79
Low education 10.1 <.01 4.64 <.01 9.32 <.01 4.50 <.01
Disease severity FEV1% pred .11 <.01 .15 <.01
Exacerbations 3.48 <.01 3.71 <.01
MRC dyspnoea 9.15 <.01 8.37 <.01
Charlson comorbidity index 1.37 <.01 .76 .19
Healthy lifestyle Physical activity (MET minutes) .001 .01 .0002 .26
Self-efﬁcacy .37 <.01 .22 <.01
Smoker .62 .74 .55 .70
Observations used in the analysis (N) 794 729 704 542 523
Dependent variable EQ-5D
Intercept .70 <.01 .63 <.01 .77 <.01 .35 <.01 .62 <.01
Adherence (PDC continuous) .03 .44 .04 .22 .06 .06 .01 .83 .02 .64
Demographics Year 2 .07 <.01 .06 <.01 .07 <.01 .06 <.01 .07 <.01
Age .001 .25 .002 .02 .001 .30 .001 .19
Men .06 <.01 .04 .03 .07 <.01 .04 .02
Low education .09 <.01 .05 <.01 .08 <.01 .05 .02
Disease severity FEV1% pred .0002 .68 .001 .33
Exacerbations .02 <.01 .02 .02
MRC dyspnoea .05 <.01 .04 <.01
Charlson comorbidity index .04 <.01 .03 <.01
Healthy lifestyle Physical activity (MET minutes) 6.8e-7 .78 4.6e-6 .05
Self-efﬁcacy .005 <.01 .004 <.01
Smoker .02 .37 .03 .17
Observations used in the analysis (N) 827 760 733 555 535
CCQ¼ Clinical COPD Questionnaire; SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions; PDC¼ Proportion of Days Covered; FEV1%
pred ¼ predicted percentage of Forced Expiratory Volume in 1 s; MRC ¼ Medical Research Council; IPAQ¼ International Physical Activity Questionnaire; MET ¼ Metabolic
Equivalent Time.
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
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Appendix 6
Linear mixed models using the minimum PDC if patients used medications from different maintenance medication categories (LABA, LAMA, ICS, LABA/ICS combinations)
b P-value b P-value b P-value b P-value b P-value
Dependent variable CCQ
Intercept 1.48 <.01 1.23 <.01 1.10 <.01 2.72 <.01 1.85 <.01
Adherent (PDC 80%) .06 .41 .03 .70 .01 .89 .04 .61 .04 .50
Year 2 .20 <.01 .30 <.01 .22 <.01 .32 <.01 .21 <.01
Demographics Age .001 .65 .01 .07 .004 .35 .01 .10
Men .04 .53 .07 .23 .05 .50 .07 .29
Low education .45 <.01 .22 <.01 .36 <.01 .16 .02
Disease severity FEV1% pred .01 <.01 .005 .01
Exacerbations .15 <.01 .14 <.01
MRC dyspnoea .37 <.01 .36 <.01
Charlson comorbidity index .06 <.01 .01 .63
Healthy lifestyle Physical activity (MET minutes) 2.3e-5 .02 6.0e-6 .48
Self-efﬁcacy .02 <.01 .01 <.01
Smoker .14 .11 .13 .06
Observations used in the analysis (N) 817 748 720 537 519
ependent variable SGRQ
Intercept 33.9 <.01 23.3 <.01 20.6 <.01 58.6 <.01 39.6 <.01
Adherent (PDC 80%) 2.22 .15 1.46 .35 .16 .90 2.90 .69 .44 .74
Demographics Year 2 2.10 .18 2.41 .12 .65 .59 2.90 .11 .37 .80
Age .12 .13 .05 .40 .02 .86 .05 .50
Men 2.30 .15 .72 .55 3.67 .03 .47 .73
Low education 10.2 <.01 4.69 <.01 9.32 <.01 4.48 <.01
Disease severity FEV1% pred .12 <.01 .15 <.01
Exacerbations 3.51 <.01 3.76 <.01
MRC dyspnoea 9.09 <.01 8.34 <.01
Charlson comorbidity index 1.40 <.01 .80 .17
Healthy lifestyle Physical activity (MET minutes) .001 .01 .0002 .31
Self-efﬁcacy .36 <.01 .22 <.01
Smoker .57 .76 .48 .74
Observations used in the analysis (N) 786 723 698 537 518
EQ-5D
Intercept .71 <.01 .68 <.01 .82 <.01 .37 <.01 .65 <.01
Adherent (PDC  80%) .01 .66 .01 .44 .02 .21 .01 .78 .01 .62
Demographics Year 2 .07 <.01 .06 <.01 .07 <.01 .06 <.01 .07 <.01
Age .001 .45 .002 .05 .001 .38 .001 .26
Men .07 <.01 .04 <.01 .07 <.01 .05 .01
Low education .09 <.01 .05 <.01 .08 <.01 .05 .01
Disease severity FEV1% pred .0001 .74 .0005 .35
Exacerbations .02 <.01 .02 .02
MRC dyspnoea .05 <.01 .04 <.01
Charlson comorbidity index .04 <.01 .03 <.01
Healthy lifestyle Physical activity (MET minutes) 4.6e-8 .99 3.9e-6 .10
Self-efﬁcacy .005 <.01 .004 <.01
Smoker .02 .31 .03 .13
Observations used in the analysis (N) 819 754 727 550 530
CCQ¼ Clinical COPD Questionnaire; SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions; PDC¼ Proportion of Days Covered; FEV1%
pred ¼ predicted percentage of Forced Expiratory Volume in 1 s; MRC ¼ Medical Research Council; IPAQ¼ International Physical Activity Questionnaire; MET ¼ Metabolic
Equivalent Time.
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
Appendix 7
Linear mixed models using the maximum PDC if patients used medications from different maintenance medication categories (LABA, LAMA, ICS, LABA/ICS combinations).
b P-value b P-value b P-value b P-value b P-value
Dependent variable CCQ
Intercept 1.39 <.01 1.21 <.01 1.11 <.01 2.66 <.01 1.81 <.01
Adherent (PDC  80%) .17 .02 .15 .05 .04 .52 .17 .05 .12 .09
Demographics Year 2 .30 <.01 .30 <.01 .21 <.01 .32 <.01 .20 <.01
Age .001 .87 .01 .05 .005 .26 .01 .06
Men .03 .65 .08 .19 .04 .64 .08 .22
Low education .45 <.01 .22 <.01 .35 <.01 .16 .02
Disease severity FEV1% pred .01 <.01 .004 .02
Exacerbations .15 <.01 .14 <.01
MRC dyspnoea .37 <.01 .37 <.01
Charlson comorbidity index .06 .01 .01 .75
Healthy lifestyle Physical activity (MET minutes) 2.2e-5 .03 6.3e-6 .47
Self-efﬁcacy .02 <.01 .01 <.01
Smoker .14 .09 .14 .06
Observations used in the analysis (N) 818 749 721 542 520
(continued on next page)
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Appendix 7 (continued )
b P-value b P-value b P-value b P-value b P-value
Dependent variable SGRQ
Intercept 31.1 <.01 22.3 <.01 22.2 <.01 57.2 <.01 38.7 <.01
Adherent (PDC  80%) 5.75 <.01 4.81 <.01 1.43 .27 3.34 .06 1.87 .19
Demographics Year 2 2.19 .15 2.41 .12 .62 .60 2.89 .11 .38 .79
Age .10 .22 .06 .32 .03 .76 .06 .42
Men 2.13 .17 .80 .51 3.43 .05 .34 .81
Low education 9.99 <.01 4.70 <.01 9.14 <.01 4.41 <.01
Disease severity FEV1% pred .11 <.01 .15 <.01
Exacerbations 3.51 <.01 3.76 <.01
MRC dyspnoea 9.09 <.01 8.37 <.01
Charlson comorbidity index 1.36 <.01 .73 .20
Healthy lifestyle Physical activity (MET minutes) .001 .01 .0002 .30
Self-efﬁcacy .36 <.01 .22 <.01
Smoker .48 .79 .45 .76
Observations used in the analysis (N) 820 724 699 538 519
Dependent variable EQ-5D
Intercept .72 <.01 .69 <.01 .82 <.01 .39 <.01 .66 <.01
Adherent (PDC  80%) ¡.01 .65 ¡.004 .82 .02 .34 ¡.01 .63 .001 .96
Demographics Year 2 .07 <.01 .06 <.01 .07 <.01 .06 <.01 .07 <.01
Age .001 .43 .002 .05 .001 .40 .001 .28
Men .07 <.01 .04 <.01 .07 <.01 .05 .01
Low education .09 <.01 .05 <.01 .08 <.01 .05 .01
Disease severity FEV1% pred .0001 .81 .0005 .36
Exacerbations .02 <.01 .02 .02
MRC dyspnoea .05 <.01 .04 <.01
Charlson comorbidity index .04 <.01 .03 <.01
Healthy lifestyle Physical activity (MET minutes) 5.3e-8 .98 4.0e-6 .09
Self-efﬁcacy .005 <.01 .004 <.01
Smoker .02 .33 .03 .14
Observations used in the analysis (N) 820 755 728 551 531
CCQ¼ Clinical COPD Questionnaire; SGRQ¼ Saint George's Respiratory Questionnaire; EQ-5D ¼ EuroQoL 5-Dimensions; PDC¼ Proportion of Days Covered; FEV1%
pred ¼ predicted percentage of Forced Expiratory Volume in 1 s; MRC ¼ Medical Research Council; IPAQ¼ International Physical Activity Questionnaire; MET ¼ Metabolic
Equivalent Time.
Note: a higher score on SGRQ & CCQ indicates a worse HRQoL, whereas a higher score on EQ-5D indicates a better HRQoL.
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